Inside CSL Behring's Plasma Processing Facility

Bloomberg

Small chromatography columns stand in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Small chromatography columns stand in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

Large chromatography columns stand in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Large chromatography columns stand in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

Employees work in the chromatography processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Employees work in the chromatography processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

An employee walks through the chromatography processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

An employee walks through the chromatography processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

A sign points to different sections of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

A sign points to different sections of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

A sign points to different sections of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

A sign points to different sections of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

An employee inspects a valve on a buffer cylinder in the chromatography processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

An employee inspects a valve on a buffer cylinder in the chromatography processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

Small chromatography columns stand in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Small chromatography columns stand in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

Metal piping used to connect cylinders hang on a rack in the chromatography processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Metal piping used to connect cylinders hang on a rack in the chromatography processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

Large chromatography columns and valves stand in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Large chromatography columns and valves stand in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

The top of a large chromatography column is seen in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

The top of a large chromatography column is seen in the processing section of the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Inside CSL Behring's Plasma Processing Facility

Bloomberg

Piping used for heat exchange stands between buffers and chromatography columns at the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images

Piping used for heat exchange stands between buffers and chromatography columns at the CSL Behring plasma processing facility, a unit of CSL Ltd., in Melbourne, Australia, on Wednesday, March 20, 2013. CSL, the world's second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects. Photographer: Carla Gottgens/Bloomberg via Getty Images